A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2

References

• Soerensen AV, Donskov F, Hermann GG, Jensen NV, Petersen A, Spliid H, et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer group (DARENCA) study-2. Eur J Cancer 2014;50:553–62.
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763–73.
   PubMed Web of Science ®Google Scholar
• Bono P, Rautiola J, Utriainen T, Joensuu H. Hypertension as a predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 2011;50:569–73.
   PubMed Web of Science ®Google Scholar
• Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P. Sunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patients. BJU Int Epub 2014 Sep 23.
   PubMedGoogle Scholar
• Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: Blessing or curse? Cancer 2011;117:534–44.
   PubMed Web of Science ®Google Scholar
• Jeppesen AN, Jensen HK, Donskov F, Marcussen N, von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010;102:867–72.
   PubMed Web of Science ®Google Scholar
• Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, et al. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. Int J Urol 2012;19:1050–7.
   PubMed Web of Science ®Google Scholar
• Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014;65:723–30.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530–40.
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009;27:5794–9.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–96.
   PubMed Web of Science ®Google Scholar
• Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Négrier S, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group. Clin Cancer Res 2011;17:5443–50.
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. Lancet Oncol 2013;14:141–8.
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariate prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–87.
   PubMed Web of Science ®Google Scholar
• Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13:827–3.
   PubMed Web of Science ®Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinomas. J Clin Oncol 2006;24:1997–2005.
   PubMed Web of Science ®Google Scholar
• Hashizume M, Higuchi Y, Uchiyama Y, Mihara M. IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 2011;54:92–9.
   PubMed Web of Science ®Google Scholar
• Marfarlane R, Heng DY, Xie W, Knox JJ, McDermott DF, Rini BI, et al. The impact of kidney function on the outcome of metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2012;118:365–70.
   PubMed Web of Science ®Google Scholar
• Spital A. Diuretic-induced hyponatremia. Am J Nephrol 1999;19:447–52.
   PubMed Web of Science ®Google Scholar
• Gankam-Kengne F, Ayers C, Khera A, de Lemos J, Maalouf NM. Mild hyponatremia is associated with increased risk of death in an ambulatory setting. Kidney Int 2013;83:700–6.
   PubMed Web of Science ®Google Scholar
• Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cell cancer patients treated with sorafenib and sunitinib. World J Urol 2011;29:807–13.
   PubMed Web of Science ®Google Scholar
• Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999;17:529–33. Erratum in J Clin Oncol 1999;17:1330.
   PubMed Web of Science ®Google Scholar
• Lankhorst S, Kappers MH, van Esch JH, Danser AH, van der Meiracker AH. Hypertension during vascular endothelial growth factor inhibition: Focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 2014;20:135–45.
   PubMed Web of Science ®Google Scholar
• Klümpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 2011;37:251–60.
   PubMed Web of Science ®Google Scholar
• Soerensen AV, Donskov F, Kjellberg J, Ibsen R, Hermann GG, Jensen NV, et al. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: National results from Darenca study 2. Eur Urol 2014;68:516–22.
   PubMed Web of Science ®Google Scholar